Abivax S.A.
ABVX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001956827
No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; 303 institutions reported holding it in 13F filings for Q2 2026, worth $7.18B in total; Maverick Capital is the only superinvestor holding it.
Other share classesAAVXF
13F holders, Q4 2025
Institutional positions in Abivax S.A. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 247
- +83 vs. Q3 2025
- Shares held
- 56.3M
- +4.35M (+8.4%) vs. Q3 2025
- Total value
- $7.61B
- +$3.20B (+72.6%) vs. Q3 2025
- New holders
- 107
- 76 more added
- Sold out
- 24
- 50 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 303 | $7.18B |
| Q1 2026 | 254 | $5.53B |
| Q4 2025 | 247 | $7.61B |
| Q3 2025 | 165 | $4.41B |
| Q2 2025 | 43 | $234.6M |
| Q1 2025 | 46 | $198.5M |
| Q4 2024 | 48 | $218.6M |
| Q3 2024 | 40 | $312.8M |
| Q2 2024 | 38 | $371.6M |
| Q1 2024 | 36 | $334.2M |
| Q4 2023 | 30 | $227.8M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Abivax S.A.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 359,305 | $48.5M | 3.13% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 367,900 | $49.6M | 1.02% | −12,100−3.2% | Reduced |
| Frazier Life Sciences Management, L.P. | 378,300 | $51.0M | 1.37% | 00.0% | Unchanged |
| First Turn Management, LLC | 381,233 | $51.4M | 5.87% | +89,413+30.6% | Added |
| Farallon Capital Management, L.L.C. | 387,000 | $52.2M | 0.27% | −418,000−51.9% | Reduced |
| StemPoint Capital LP | 391,783 | $52.8M | 9.07% | +225,510+135.6% | Added |
| Logos Global Management LP | 400,000 | $53.9M | 3.59% | −15,000−3.6% | Reduced |
| Silverarc Capital Management, LLC | 422,193 | $56.9M | 8.24% | −117,511−21.8% | Reduced |
| Jane Street Group, LLC | 423,257 | $57.1M | 0.07% | +355,455+524.3% | Added |
| Standard Life Aberdeen plc | 426,658 | $57.5M | 0.09% | −360,759−45.8% | Reduced |
| BlackRock, Inc. | 436,713 | $58.9M | 0.00% | +436,713 | New |
| Franklin Resources Inc | 449,121 | $60.6M | 0.01% | −66,969−13.0% | Reduced |
| JPMorgan Chase & Co | 455,923 | $61.5M | 0.00% | +455,923 | New |
| Jefferies Financial Group Inc. | 457,325 | $61.7M | 0.51% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 458,343 | $61.8M | 1.13% | +69,735+17.9% | Added |
| Affinity Asset Advisors, LLC | 505,000 | $68.1M | 4.89% | +145,000+40.3% | Added |
| Boothbay Fund Management, LLC | 507,881 | $68.5M | 1.80% | −90,050−15.1% | Reduced |
| BVF Inc | 508,031 | $68.5M | 2.31% | −50,000−9.0% | Reduced |
| Ensign Peak Advisors, Inc | 518,347 | $69.9M | 0.12% | +62,663+13.8% | Added |
| Bank of America Corp | 522,289 | $70.4M | 0.01% | +426,696+446.4% | Added |
| Adage Capital Partners GP, L.L.C. | 550,000 | $74.2M | 0.11% | −427,629−43.7% | Reduced |
| Citadel Advisors LLC | 563,747 | $76.0M | 0.05% | −118,038−17.3% | Reduced |
| Artia Global Partners LP | 600,747 | $81.0M | 13.02% | +375,294+166.5% | Added |
| Saturn V Capital Management LLC | 649,179 | $87.5M | 16.07% | −152,045−19.0% | Reduced |
| Price T Rowe Associates Inc | 651,644 | $87.9M | 0.01% | +171,775+35.8% | Added |
| Eversept Partners, LP | 657,834 | $88.7M | 4.97% | +231,335+54.2% | Added |
| Janus Henderson Group PLC | 667,761 | $90.0M | 0.04% | +313,027+88.2% | Added |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 691,973 | $93.3M | 8.28% | −39,550−5.4% | Reduced |
| Millennium Management LLC | 741,060 | $99.9M | 0.07% | −358,970−32.6% | Reduced |
| Susquehanna International Group, LLP | 754,836 | $101.8M | 0.14% | +720,222+2,080.7% | Added |
| Octagon Capital Advisors LP | 756,000 | $102.0M | 12.76% | −569,000−42.9% | Reduced |
| Deutsche Bank AG | 764,899 | $103.2M | 0.03% | +764,899 | New |
| Lord, Abbett & Co. LLC | 849,732 | $114.6M | 0.35% | +513,026+152.4% | Added |
| Baker Bros. Advisors LP | 875,796 | $118.1M | 0.69% | 00.0% | Unchanged |
| Westfield Capital Management Co LP | 1,009,966 | $136.2M | 0.57% | +1,009,966 | New |
| ADAR1 Capital Management, LLC | 1,317,329 | $177.6M | 13.29% | −33,497−2.5% | Reduced |
| Cormorant Asset Management, LP | 1,350,000 | $182.1M | 10.32% | −600,000−30.8% | Reduced |
| FMR LLC | 1,365,657 | $184.2M | 0.01% | −65,016−4.5% | Reduced |
| Paradigm Biocapital Advisors LP | 1,417,473 | $191.2M | 5.12% | −146,723−9.4% | Reduced |
| Caligan Partners LP | 1,451,924 | $195.8M | 17.92% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 1,900,000 | $256.2M | 9.40% | +900,000+90.0% | Added |
| Point72 Asset Management, L.P. | 2,409,154 | $324.9M | 0.51% | −516,198−17.6% | Reduced |
| Morgan Stanley | 3,151,994 | $425.1M | 0.03% | +1,681,277+114.3% | Added |
| Darwin Global Management, Ltd. | 3,178,501 | $439.7M | 8.90% | +14,000+0.4% | Added |
| UBS Group AG | 4,423,906 | $596.6M | 0.12% | −37,356−0.8% | Reduced |
| TCG Crossover Management, LLC | 7,111,596 | $959.0M | 31.74% | 00.0% | Unchanged |
| PSquared Asset Management AG | 240 | – | – | +240 | New |
| Fairmount Funds Management LLC | 0 | $0 | 0.00% | −713,434−100.0% | Sold out |
| VR Adviser, LLC | 0 | $0 | 0.00% | −576,729−100.0% | Sold out |
| RTW Investments, LP | 0 | $0 | 0.00% | −350,000−100.0% | Sold out |
| Bronte Capital Management Pty Ltd. | 0 | $0 | 0.00% | −156,747−100.0% | Sold out |
| Great Point Partners LLC | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −55,197−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −53,078−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| Longaeva Partners L.P. | 0 | $0 | 0.00% | −32,886−100.0% | Sold out |
| Quinn Opportunity Partners LLC | 0 | $0 | 0.00% | −31,000−100.0% | Sold out |
| Privium Fund Management B.V. | 0 | $0 | 0.00% | −30,412−100.0% | Sold out |
| Polygon Management Ltd. | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −19,095−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −16,608−100.0% | Sold out |
| Jain Global LLC | 0 | $0 | 0.00% | −11,099−100.0% | Sold out |
| Dymon Asia Capital (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −9,332−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −9,294−100.0% | Sold out |
| Integrated Wealth Concepts LLC | 0 | $0 | 0.00% | −3,633−100.0% | Sold out |
| Marex Group plc | 0 | $0 | 0.00% | −3,402−100.0% | Sold out |
| Ashton Thomas Securities, LLC | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| Stonepine Capital Management, LLC | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |
| Gordian Capital Singapore Pte Ltd | 0 | $0 | 0.00% | −900−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |